JO
RCKT icon

John Overdeck’s Rocket Pharmaceuticals RCKT Stock Holding History

John Overdeck’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Sell
315,761
-781,862
-71% -$2.6M ﹤0.01% 3557
2026
Q1 		$3.93M Sell
1,097,623
-1,034,306
-49% -$4.11M ﹤0.01% 2189
2025
Q4 		$7.48M Buy
2,131,929
+522,247
+32% +$1.79M 0.01% 1347
2025
Q3 		$5.25M Sell
1,609,682
-115,678
-7% -$364K 0.01% 1426
2025
Q2 		$4.23M Buy
+1,725,360
New +$8.74M 0.01% 1333
2025
Q1 		– Sell
-41,142
Closed -$517K – 3444
2024
Q4 		$517K Buy
41,142
+19,326
+89% +$291K ﹤0.01% 2526
2024
Q3 		$403K Sell
21,816
-1,275
-6% -$26.1K ﹤0.01% 2557
2024
Q2 		$497K Sell
23,091
-126,917
-85% -$2.91M ﹤0.01% 2372
2024
Q1 		$4.04M Sell
150,008
-104,908
-41% -$2.98M 0.01% 1092
2023
Q4 		$7.64M Sell
254,916
-141,423
-36% -$3.12M 0.02% 788
2023
Q3 		$8.12M Buy
396,339
+352,239
+799% +$6.4M 0.02% 679
2023
Q2 		$876K Sell
44,100
-102,179
-70% -$2.06M ﹤0.01% 2011
2023
Q1 		$2.51M Buy
146,279
+74,329
+103% +$1.46M 0.01% 1251
2022
Q4 		$1.41M Sell
71,950
-267,049
-79% -$4.92M ﹤0.01% 1518
2022
Q3 		$5.41M Buy
338,999
+120,037
+55% +$1.87M 0.02% 726
2022
Q2 		$3.01M Sell
218,962
-25,688
-10% -$306K 0.01% 982
2022
Q1 		$3.88M Sell
244,650
-3,464
-1% -$59.8K 0.01% 1037
2021
Q4 		$5.42M Buy
248,114
+40,239
+19% +$1.1M 0.01% 1154
2021
Q3 		$6.21M Buy
207,875
+39,306
+23% +$1.43M 0.01% 1074
2021
Q2 		$7.47M Sell
168,569
-162,717
-49% -$7.07M 0.02% 976
2021
Q1 		$14.7M Buy
331,286
+227,806
+220% +$12.5M 0.04% 546
2020
Q4 		$5.67M Buy
103,480
+88,973
+613% +$3.24M 0.02% 854
2020
Q3 		$332K Sell
14,507
-8,479
-37% -$209K ﹤0.01% 2522
2020
Q2 		$481K Buy
+22,986
New +$414K ﹤0.01% 2023
2015
Q4 		– Sell
-8,798
Closed -$331K – 2931
2015
Q3 		$331K Buy
+8,798
New +$404K ﹤0.01% 1744

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

John Overdeck's RCKT Position: Q2 2026 in Review

John Overdeck reduced its Rocket Pharmaceuticals (RCKT) stake by 71% in Q2 2026, selling an estimated $2.6M and leaving 315,761 shares worth $1.08M. The position accounts for ﹤0.01% of the portfolio, ranked #3557.

John Overdeck first reported a position in RCKT in Q3 2015 and has held it in 25 quarters since. The position peaked at $14.7M in Q1 2021. 178 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • John Overdeck held 315,761 shares of Rocket Pharmaceuticals worth $1.08M as of Q2 2026.
  • John Overdeck sold 781,862 Rocket Pharmaceuticals shares in Q2 2026, an estimated $2.6M.
  • Rocket Pharmaceuticals made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3557 holding.
  • John Overdeck first reported a position in Rocket Pharmaceuticals in Q3 2015 and has held it in 25 quarters since.
  • John Overdeck's Rocket Pharmaceuticals position peaked at $14.7M in Q1 2021.
  • 178 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.